Improvement of type 2 diabetes mellitus after gastric cancer surgery: Short-term outcome analysis after gastrectomy

Table 4 Factors for diabetic control at postoperative 12 mo n (%)

	Stationary (n = 27)	Improved or remission (n = 37)	1P (univariate)
Age (yr)	64.3 ± 7.2	62.2 ± 8.4	0.5822
Sex			0.789
Male	19 (44.2)	24 (55.8)
Female	8 (38.1)	13 (61.9)
BMI, preop (kg/m2)	24.5 ± 4.0	24.9 ± 3.0	0.4342
BMI
3 mo	94.4% ± 5.0%	91.2% ± 5.3%	0.0182
6 mo	93.7% ± 6.8%	90.4% ± 5.7%	0.0362
12 mo	93.8% ± 9.1%	88.9% ± 7.8%	0.0412
Smoking			0.043
Yes	16 (57.1)	12 (42.9)
No	11 (30.6)	25 (69.4)
Alcohol history			0.132
No	13 (34.2)	25 (65.8)
Yes	14 (53.8)	12 (46.2)
DM duration (yr)			0.013
> 10	10 (76.9)	3 (23.1)
5-10	8 (40.0)	12 (60.0)
< 5	9 (29.0)	22 (71.0)
Family history of DM			1.000
No	22 (42.3)	30 (57.7)
Yes	5 (41.7)	7 (58.3)
Operation type			0.799
STG BI	15 (41.7)	21 (58.3)
STG BII	6 (37.5)	10 (62.5)
TG	6 (50.0)	6 (50.0)
Preop FBS	152.1 ± 43.6	145.6 ± 40.3	0.6242
Preop HbA1c	6.9 ± 0.8	7.4 ± 1.2	0.3132
Preop Insulin	21.7 ± 26.3	19.0 ± 17.8	0.8042
Preop C-peptide	3.1 ± 2.2	3.3 ± 1.9	0.5092
Preop HOMA-IR	9.2 ± 12.8	7.3 ± 8.0	0.8352

¹χ²;

²Mann-Whitney U test, mean ± SD. Significant values are indicated in bold face. BMI: Body mass index, BMI (%) refers to the percentage of BMI at postoperative follow-up. DM: Diabetes mellitus; STG BI: Subtotal gastrectomy with Billroth I anastomosis; STG BII: Subtotal gastrectomy with Billroth II anastomosis; TG: Total gastrectomy; FBS: Fasting blood glucose; HOMA-IR: Homeostasis model assessment-estimated insulin resistance.